Le Thu Thuy1, Vu Thi Thu Huyen1, Nguyen Thien Phong1, Duong Viet Tuan1, Luu Thuy Linh1, Le Huong Giang1, Pham Nu Hanh Van1, Nguyen Thanh Binh1
1.Hanoi University of Pharmacy
Objectives: To systematically review the cost-effectiveness of tamsulosin 0.4mg and dutasteride 0.5mg combination therapy compared with tamsulosin 0.4mg or dutasteride 0.5mg monotherapy or watchful waiting for the treatment of benign prostatic hyperplasia.
Methods: A systematic search for cost-effectiveness analysis of dutasteride and tamsulosin was performed using PubMed, Cochrane, National Institute for Health and Care Excellence, Canadian Agency for Drugs and Technologies in Health, Scottish Medicines Consortium, Pharmaceutical Benefits Advisory Committee, and Agency for Care Effectiveness. Two researchers independently determined the final articles and a third researcher resolved any discrepancies. Studies’ characteristics and cost-effectiveness data were extracted and organized.
Results: Seven articles were included in the final review. Cumulative discounted costs and quality-adjusted life years per patient were both higher with combination therapy than with monotherapy or watchful waiting. Over a lifetime horizon, the incremental cost-effectiveness ratio for combination therapy ranged from $908.13 to $20,095.
Conclusions: All studies have shown that QALYs of the combination therapy were higher than those of monotherapy or watchful waiting, and the combination therapy was cost-effective with the national threshold or the threshold recommended by WHO.
Source: Journal of Pharmaceutical Research and Drug Information, 13(5), 17–24, 2022.
Link: https://jprdi.vn/JP/article/view/67